E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:
beta-thalassaemia major
Sickle cell disease |
Ai soggetti trattati con il prodotto medicinale in uno studio clinico sponsorizzato da bluebird bio sarà chiesto di partecipare a questo studio di follow-up a lungo termine per monitorare la sicurezza ed efficacia del prodotto medicinale. Ad oggi, i soggetti in questo studio sono stati trattati con il prodotto medicinale di terapia genica blubirdbio sviluppato per il trattamento delle seguente indicazioni: ß-talassemia grave malattia a cellule falciformi |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055579 |
E.1.2 | Term | Sickle-cell beta thalassemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Monitor the long-term safety and efficacy of gene therapy drug products used in bluebird bio-sponsored clinical studies in treated subjects with hemoglobinopathies. Monitor the long term efficacy of the drug product. |
Monitorare la sicurezza a lungo termine del prodotto medicinale di terapia genica usato in studi clinici sponsorizzati da bluebird bio in soggetti trattati affetti da emoglobinopatie. Monitorare l’efficacia a lungo termine del prodotto medicinale. |
|
E.2.2 | Secondary objectives of the trial |
Not Applicable |
Non applicabile |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of written informed consent for this study by subject, or as applicable, subject’s parent(s)/ legal guardian(s).
2. Previously treated with drug product for therapy of a hemoglobinopathy in a bluebird bio-sponsored clinical study.
3. Able to comply with study requirements
|
1. Rilascio del consenso informato scritto per questo studio da parte del soggetto o, se pertinente, del/i genitore/i/tutore/i legale/i del soggetto 2. Trattamento con un prodotto medicinale per la terapia di una emoglobinopatia in uno studio clinico sponsorizzato da bluebird bio 3. Capacità di attenersi ai requisiti dello studio |
|
E.4 | Principal exclusion criteria |
1.Met the VCN discontinuation criterion, as follows:
Undetectable VCN (<0.0003 copies per diploid geome) in peripheral blood cells for 2 consecutive measurements at least 1 month apart and at least 12 months after drug product infusion. |
1. Soddisfacimento del criterio di interruzione della misurazione del VCN nello studio originario, come segue: il soggetto presenta VCN non rilevabile (<0,0003 copie per genoma diploide) nelle cellule del sangue periferico per 2 misurazioni consecutive eseguite a distanza di almeno 1 mese e almeno 12 mesi dopo l’infusione del prodotto medicinale |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety Endpoints include:
- Overall survival
- All drug product-related adverse events (AEs) through Year 15 post hematopoietic stem cell transplantation (HSCT)
- All serious adverse events (SAEs) through Year 15 post-HSCT
- Incidence of vector-derived RCL, assessed from archived samples as clinically-indicated
- Characterization of events of insertional mutagenesis leading to clonal dominance or leukemia
-Laboratory tests as specified
Efficacy evaluations will be performed throughout the study and longterm efficacy will be assessed, as feasible, based on data collected in this study. |
Gli endpoint di sicurezza includono: • Sopravvivenza complessiva • Tutti gli EA correlati al prodotto medicinale fino all’Anno 15 post-HSCT • Tutti i SAE fino all’Anno 15 post-HSCT (indipendentemente dalla correlazione con il prodotto medicinale) • Incidenza di RCL derivati dal vettore, valutata dai campioni d’archivio come clinicamente indicato • Caratterizzazione degli eventi di mutagenesi inserzionale che conducono a dominanza clonale o leucemia • Esami di laboratorio come specificato
Le valutazioni di efficacia saranno eseguite per tutta la durata dello studio e l’efficacia a lungo termine sarà valutata, se fattibile, in base ai dati raccolti durante questo studio. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Follow-up visits are scheduled every 6 months through Year 5 (Month 60) post-transplant, and then annually thereafter through Year 15 post-transplant. |
Le visite di follow up sono pianificate ogni 6 mesi fino al 5o anno (mese 60) post-trapianto, e poi annualmente dopo il 15o anno dopo il trapianto. |
|
E.5.2 | Secondary end point(s) |
Not Applicable |
Not Applicable |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Not Applicable |
Not Applicable |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Long-term follow up |
Long-term follow up |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Thailand |
United States |
France |
Germany |
Greece |
Italy |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 13 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 13 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |